Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing R...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: April 19, 2024

Investigation by the RCMP National Child Exploitation Crime Centre results in the arrest of a Gatineau man for distribution and • New Jersey Natural Gas to Reduce Fleet Emissions with Neste MY Renewable Diesel • Energy Transition Accelerator Advances with New Secretariat, Expert Consultative Group • USAA to Gift Vehicles to Military and Their Families in 2024 • Avangrid Thanks Southern Connecticut Gas Employee for 51 Years of Service • University of Phoenix College of Nursing Faculty Leadership Selected for Prestigious Fellows of the American Association of Nurs • H2 Green Mining and Ohmium Sign Agreement to Boost Green Hydrogen in Chile • Eaton to announce first quarter 2024 earnings on April 30, 2024 • El Car Wash Partners With “CARD” to Support Neurodiversity in the Workplace • Hartford HealthCare makes Earth-friendly pledge of carbon neutrality by 2050 • MCR and BLT Complete $632 Million Refinancing of 53-Hotel Portfolio • Prime Minister announces appointment of the next Commissioner of the Northwest Territories • NABCO 2024 Leadership Summit & Retreat: Uniting African-American County Officials for Empowerment and Advocacy • Strengthening Canadian research and innovation • Adhering to Asthma Medication is Safe for Pregnant Women with Asthma • Anta Kids joins hands with teenagers to launch running events in five cities, showcasing the essence of Chinese culture • Divert Announces Purchase of New Site in Lexington, North Carolina for Future Integrated Diversion & Energy Facility • Kellanova and Shaw's join No Kid Hungry to help end summer hunger for kids and families in Maine • Clarification of Details Regarding Oceansix's Engagement with RB Milestone Group LLC • R.H. Boyd Hosts Third Annual Legacy Ball Honoring Influential Leaders and Supporting Scholarships and Grants

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON , February 02 /Businesswire/ - Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, granted stock options to purchase 1,800 shares of Astria’s common stock on February 1, 2023 under Astria’s 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria.

The options were granted as an inducement material to an employee or employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $13.36, which is equal to the closing price of Astria’s common stock on February 1, 2023 (the “Grant Date”), and will vest over a four-year period, with 25% of shares vesting on the first anniversary of the employee’s employment start date (which preceded the Grant Date) and the remaining shares vesting monthly on a ratable basis over the following 36 months, subject to the employee’s continued employment with Astria on such vesting dates. The options are subject to the terms and conditions of the 2022 Inducement Stock Incentive Plan and the terms and conditions of an award agreement covering the grant.

About Astria Therapeutics:

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Learn more about our company on our website, www.astriatx.com, or follow us on Twitter and Instagram @AstriaTx and on Facebook and LinkedIn.